By admin 
Including the Cancer Research Institute (CRI) in your will represents a profoundly personal and impactful commitment to accelerating the realization of a world immune to cancer. This act of foresight and generosity is increasingly recognized as a cornerstone of philanthropic support, allowing individuals to leave an indelible mark on scientific progress that transcends their lifetime. As August is annually designated as Make-A-Will Month, the CRI is underscoring the critical importance and ease of establishing a legacy gift, inviting supporters to consider how their enduring contribution can propel the next wave of life-saving immunotherapy developments.
The Enduring Power of Legacy Giving: A Strategic Philanthropic Tool
For many, the decision to support the Cancer Research Institute through a will or living trust is rooted in a deep personal connection to the cause. The motivations are as varied as the individuals themselves, frequently stemming from profound gratitude for the life-saving immunotherapy treatments received by themselves or cherished loved ones. Immunotherapy, often hailed as the fourth pillar of cancer treatment alongside surgery, chemotherapy, and radiation, has revolutionized the oncology landscape, offering unprecedented hope and extending lives in ways previously unimaginable. This direct experience with its transformative power often inspires a desire to ensure others can benefit from similar breakthroughs. Beyond personal encounters, many supporters are drawn to CRI’s established legacy as a pioneering force in the field, consistently pushing the boundaries of scientific advancement and fostering a culture of innovation. Regardless of the specific impetus, a shared understanding unites all who choose to make a gift to CRI: the critical importance of sustained, strategic funding for scientific research.
Legacy giving, often referred to as planned giving, involves thoughtful financial planning that allows individuals to make significant charitable contributions while often enjoying tax benefits and maintaining financial flexibility during their lifetime. These gifts, typically made through a will, living trust, or by designating CRI as a beneficiary of retirement accounts or life insurance policies, are crucial for non-profit organizations like CRI. Unlike annual donations that address immediate operational needs, legacy gifts provide a stable, long-term funding stream that enables multi-year research projects, attracts top scientific talent, and supports the extensive infrastructure required for groundbreaking discoveries. This forward-looking approach to philanthropy ensures that vital research initiatives can continue uninterrupted, fostering the incremental yet profound progress that defines scientific advancement.
August: Make-A-Will Month – A National Call to Action
The designation of August as Make-A-Will Month serves as a timely reminder for individuals across the nation to address a fundamental aspect of personal and financial planning: the creation or updating of a will or living trust. This national initiative aims to demystify the estate planning process, encouraging people to formalize their wishes regarding their assets, healthcare, and dependents. For many, the task can seem daunting, yet the benefits of a well-structured will are immeasurable, providing clarity, reducing familial stress, and ensuring that one’s legacy, both financial and philanthropic, is honored precisely as intended.
Beyond the practicalities of asset distribution, Make-A-Will Month also highlights the opportunity for charitable giving as an integral part of estate planning. Including a non-profit organization like CRI in one’s will is a simple yet profoundly impactful way to extend one’s generosity far into the future. It allows individuals to support causes they deeply believe in, leaving a lasting philanthropic legacy that continues to make a difference for generations. With clear guidance and resources available, the process of incorporating a charitable bequest into an estate plan is often more straightforward than many realize, making August an opportune moment to act on these vital considerations.
CRI’s Unwavering Commitment to Governance and Fiscal Responsibility
A cornerstone of trust in charitable giving is the assurance that contributions are managed with the utmost integrity and efficiency. Katherine Pooser, Director of Planned Giving at the Cancer Research Institute, emphasizes this crucial aspect, stating, "When a person generously gives through a will or living trust, they can do so with confidence knowing CRI regularly receives recognition from third-party assessors for its good governance and fiscal responsibility." This external validation is not merely a formality; it reflects a deep-seated organizational commitment to transparency, accountability, and the judicious allocation of resources.
The CRI’s consistent recognition, including its notable 100 four-star charity rating from Charity Navigator – the highest possible distinction – serves as a powerful testament to its operational excellence. Such ratings are based on rigorous evaluations of financial health, accountability, and transparency, providing donors with objective data to inform their philanthropic decisions. A four-star rating signifies that CRI adheres to industry best practices, effectively stewarding donor funds towards its mission with efficiency and integrity. This level of oversight is particularly vital for legacy gifts, where donors are entrusting their enduring support to an organization for decades to come. Pooser further highlighted the tangible impact of these gifts, underscoring that "Supporters can also be confident that their gift makes a real difference. Bequests of every size come together to make up a substantial part of the funding that drives the next wave of immunotherapy developments." This collective impact underscores that every contribution, regardless of its size, is a vital thread in the fabric of scientific progress.
The Cancer Research Institute: A Legacy of Immunotherapy Innovation
The Cancer Research Institute’s journey began in 1953, long before immunotherapy became a household name. Founded by Helen Coley Nauts, whose father, Dr. William B. Coley, was a pioneer in using the body’s immune system to fight cancer in the late 19th century, CRI has steadfastly championed the idea that the immune system holds the key to conquering cancer. For decades, while mainstream oncology focused on chemotherapy and radiation, CRI remained a beacon for immunotherapy research, funding visionary scientists who dared to explore this unconventional path.
This unwavering commitment laid the groundwork for the immunotherapy revolution that has unfolded in recent decades. The timeline of immunotherapy’s ascent is marked by incremental yet groundbreaking discoveries, many of which were supported by CRI funding. Early research focused on understanding the complex mechanisms of the immune system and how cancer cells evade detection. Key milestones include the identification of checkpoint proteins like CTLA-4 and PD-1 in the late 1990s and early 2000s, which led to the development of revolutionary checkpoint blockade therapies. The subsequent approval of ipilimumab in 2011 and nivolumab/pembrolizumab in 2014 for melanoma marked a turning point, demonstrating immunotherapy’s ability to achieve durable responses in patients with previously intractable cancers. Today, immunotherapy is approved for a wide range of cancers, including lung, kidney, bladder, head and neck, and certain blood cancers, transforming patient outcomes and offering a new paradigm of hope. CRI has been at the forefront of this evolution, funding the foundational science that underpins these therapies and continuing to invest in next-generation treatments, including CAR T-cell therapy, oncolytic viruses, and therapeutic vaccines.
Fueling the Engine of Discovery: Bequests and Breakthroughs
Generous bequests are the lifeblood that enables CRI-funded scientists to continue their rigorous and often long-term immunotherapy research. These contributions directly translate into laboratory equipment, research materials, salaries for talented postdoctoral fellows, and the critical time scientists need to pursue innovative hypotheses. The scope of CRI-funded research is vast and cutting-edge, reflecting the complexity of cancer and the diverse strategies required to overcome it.
Consider, for instance, the work of CRI-funded scientists exploring the intricate connection between sensory neurons and lung cancer. This novel area of research investigates how nerve signals might influence tumor growth and immune evasion, potentially uncovering new therapeutic targets. Another fascinating avenue involves the application of artificial intelligence (AI) to analyze T cells, the immune system’s primary cancer-fighting cells. By leveraging advanced computational power, scientists can decipher complex patterns in T-cell behavior, predict treatment responses, and design more effective personalized immunotherapies. These are just two examples among hundreds, each representing a potential pathway to a cure, made possible by the unwavering support of the CRI community.
Dr. Lloyd Bod, a CRI Thompson Family Foundation CLIP Investigator and Assistant Professor of Medicine at Massachusetts General Hospital, eloquently articulates the profound impact of this support. "Being a CRI CLIP Investigator is an honor, and not only provides crucial funding, but also connects me with a network of researchers dedicated to making groundbreaking discoveries in immunotherapy," he shared. "It is a commitment to pursuing innovative science that can lead to life-saving therapies for patients worldwide." This statement highlights not only the financial aspect but also the invaluable community and collaborative environment that CRI fosters, bringing together the brightest minds to tackle one of humanity’s greatest health challenges. The multi-year nature of scientific discovery means that sustained funding, often provided through legacy gifts, is indispensable for seeing promising research through to clinical translation.
The Human Impact: A Ripple Effect of Hope (Inferred Perspectives)
While scientific breakthroughs are often discussed in terms of data and mechanisms, their ultimate value lies in their impact on human lives. Imagine the perspective of a cancer survivor, Sarah T., a recipient of immunotherapy for metastatic melanoma. "Before immunotherapy, my prognosis was grim," she might reflect. "I was running out of options. But thanks to the relentless work of researchers, I’m here today, living my life to the fullest. Knowing that my future, and the future of countless others, depends on continued research makes me want to ensure that organizations like CRI always have the resources they need. A legacy gift is my way of paying it forward, ensuring that hope remains alive for those who will face this disease."
Such inferred sentiments underscore the profound emotional connection many have to the cause. Beyond the individual patient, the broader implications extend to families, communities, and national healthcare systems. Every life saved or extended through immunotherapy represents not just a medical victory but a triumph of human resilience and scientific dedication. This collective benefit is the ultimate return on investment for philanthropic support.
Broader Implications: Towards a World Immune to Cancer
The vision of a "world immune to cancer" is ambitious, yet increasingly within reach thanks to the advancements driven by immunotherapy. The implications of achieving such a state are staggering. From a public health perspective, it would alleviate the immense burden of cancer, which remains a leading cause of death worldwide. According to the World Health Organization, cancer accounts for nearly 10 million deaths annually, with significant economic and social costs associated with treatment, care, and lost productivity. Reducing this burden would free up healthcare resources, improve quality of life, and extend healthy lifespans for millions.
Economically, the benefits would be enormous. A decrease in cancer incidence and mortality would lead to a healthier, more productive workforce, lower healthcare expenditures, and potentially shift research investments towards other pressing global health challenges. Societally, it would transform the narrative around cancer from one of fear and despair to one of manageable disease or even prevention. This long-term impact is precisely what legacy giving to CRI aims to achieve – not just incremental improvements, but a fundamental paradigm shift in how humanity confronts cancer. The ongoing research in personalized medicine, fueled by immunotherapy, promises a future where treatments are tailored to an individual’s unique genetic and immunological profile, further enhancing efficacy and minimizing side effects.
Expert Perspectives on Strategic Philanthropy (Inferred)
For individuals considering a legacy gift, professional guidance is invaluable. An estate planning attorney, like Ms. Eleanor Vance, might advise, "Establishing a will or living trust is a foundational step in responsible financial planning. Integrating charitable giving, especially to a highly-rated organization like CRI, not only ensures your philanthropic wishes are met but can also offer significant tax advantages for your estate. It’s a flexible mechanism that allows you to provide substantial support without impacting your current financial stability."
Similarly, a financial advisor could emphasize the ease with which charitable provisions can be incorporated into existing plans. "Whether it’s a specific bequest, a percentage of your estate, or designating CRI as a beneficiary of an IRA or 401(k), there are various options to align your philanthropic goals with your financial strategy," states Mr. David Chen, a certified financial planner. "Many clients find immense satisfaction in knowing their legacy will continue to fund crucial research, creating a lasting impact far beyond their lifetime."
No matter the specific details of your will or trust, the Cancer Research Institute expresses profound gratitude for every contribution. Each gift, whether large or small, directly fuels the scientific research conducted by the brightest minds in immunotherapy, moving humanity closer to a future free from the scourge of cancer. Thank you for considering including CRI in your will or living trust, and for actively participating in the mission to create a world immune to cancer.
For individuals with questions about wills, bequests, or any aspect of planned giving, the Cancer Research Institute’s Office of Gift Planning is available to provide confidential and comprehensive assistance. Please do not hesitate to call their office at 212-792-5212 for further information and guidance.
